drug_type
RELEVANT_DRUG
intervention_type
Biologic (gene-modified cellular immunotherapy)
drug_description
Autologous T lymphocytes genetically engineered to express a CD7-directed chimeric antigen receptor; administered intravenously with dose escalation to activate, proliferate, and kill CD7-positive leukemic cells via perforin/granzyme cytotoxicity, causing depletion of CD7+ malignant cells and on-target T/NK-cell aplasia.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered to express a CD7-directed chimeric antigen receptor; CAR engagement with CD7 triggers CD3ΞΆ and costimulatory signaling, activating and expanding the T cells to mediate MHC-independent cytotoxicity (perforin/granzyme and cytokine release) against CD7-positive leukemic cells, resulting in depletion of CD7+ malignant cells and on-target T/NK-cell aplasia.
drug_name
CD7 CAR-T cells
nct_id_drug_ref
NCT06585345